A PYMNTS Company

US: Impax faces drug delay antitrust suit

By  |  March 12, 2018

According to a report on Monday, March 12, Impax Laboratories went to trial over claims by major retailers and consumers that the company agreed to delay launching a generic version of Solodyn in exchange for millions of dollars from the acne medication’s manufacturer.

    Get the Full Story

    Complete the form to unlock this article and enjoy unlimited free access to all PYMNTS content — no additional logins required.

    yesSubscribe to our daily newsletter, PYMNTS Today.

    By completing this form, you agree to receive marketing communications from PYMNTS and to the sharing of your information with our sponsor, if applicable, in accordance with our Privacy Policy and Terms and Conditions.

    Jury selection began in Boston federal court in a case centered on an alleged “pay-for-delay” settlement, in which a generic manufacturer agrees to resolve legal challenges to a brand-name drug’s patents and delay making a cheaper version.

    The trial is one of a handful to have taken place since the US Supreme Court in 2013 said that such settlements, which also involve brand-name drug companies paying the generic manufacturers, can be found to be anticompetitive.

    The case is being pursued by a class of consumers and third-party insurers and by several retailers, including CVS Health, Walgreens Boots Alliance Inc and Rite Aid.

    Full Content: Reuters

    Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.